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Abstract. Hepatitis C virus (HCV) is an RNA virus that can cause liver inflammation (hepatitis) 
and has the potential to become chronic and can progress to liver cirrhosis and hepatocellular 
carcinoma.  Detection of HCV RNA infection, and genotype/subtype of HCV was performed on 
70 blood sera of patients at the Hepatology Outpatient Clinic of Dr Soetomo General Hospital, 
Surabaya, Indonesia.  Detection of HCV infection was carried out by Anti-HCV determination 
using enzyme immunoassay (EIA) technique, detection of HCV RNA by Reverse Transcription 
Polymerase Chain Reaction (RT-PCR) technique based on genome regions NS5b and 5'UTR, 
followed by electrophoresis with agarose gel. In positive PCR results, HCV genotype/subtype 
was determined by direct sequencing method using ABI 310 sequencer and sequencing results 
were analyzed by comparing the products with previously published HCV nucleotides.  Sera 
were obtained from 41 (58.6%) male and 29 (41.4%) female patients. Anti-HCV was found 
positive in 17/70 (24.29%) patients and 16/17 (94.1%) was proved to contain HCV RNA when 
determined by RT-PCR technique. Patients with positive HCV RNA have the potential to 
transmit HCV infection. From the genotype/subtype analysis of sequencing results we obtained 
2/16 (12,5%), 3/16 (18,75%) and 6/16 (37,5%), 1/16 (6,25%), 1/16 (6 , 25%), 2/16 (12,5%), 1/16 
(6,25%) HCV genotypes 1, 2, and HCV subtypes 1b, 1c, 2a, 3a, 3k respectively.Conclusion: In 
patients who went to the Hepatology Outpatient Clinic, Dr. Soetomo General Hospital Surabaya, 
we found positive Anti-HCV was 24,29%.  In 94,1% of patients with positive Anti-HCV, HCV 
RNA was still detected and HCV genotype 1 with subtype 1b were still dominant HCV subtypes. 
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1. Introduction 
Hepatitis C virus (HCV) infection is still a health problem in the world including in Indonesia and can 
be a cause of liver inflammation (hepatitis).  Hepatitis C virus has been shown to have a worldwide 
distribution, occurring among persons of all ages, ethnicity, genders,  and regions of the world [1].  
Eighty-five % (85%) HCV infections become chronic [2] and have the potential for liver cirrhosis and 
are subsequently at risk for hepatocellular carcinoma (HCC) [2, 3, 4, 5], liver failure, and death [4]. The 
other publication also  mentioned that chronic HCV infection has been linked to the development of 
HCC in many areas of the world [1]. 
Hepatitis C virus infection has parenteral transmission pathway, for example through blood 
transfusion and blood product, through sexual contact, sharing needles or HCV-contaminated devices, 
and from mother to child [6].  The population who are classified as having role a potential risk of HCV 
transmission, such as medical procedures, injections for medications and immunizations, injections 
applied outside of medical settings, tattooing, and scariﬁcation techniques, have shown wide 
geographical variations [1]. 
Antibodies to HCV (anti-HCV) are the most commonly available marker of HCV infection at 
present [4].  Detection of positive anti-HCV is also a sign that someone is infected with HCV.  Individual 
with positive  anti-HCV does not always negative for HCV RNA in the blood, so it is necessary to check 
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the presence of HCV RNA in the blood. A previous study showed that 95% of patients with positive 
anti-HCV still have HCV RNA in their blood [7].  
Hepatitis C virus is a single-stranded RNA virus, positive-sense, and classified into Hepacivirus 
genus [5] of Flaviviridae family [4, 8].  Hepatitis C virus with a length of 9.6 kb, consists of the 5' UTR, 
genes for structural proteins (Core, E1 and E2) and genes for non-structural proteins (NS1, NS2, NS3, 
NS4A, NS4B, N4A, NS5B) and 3'UTR [3, 9].  Hepatitis C virus shows high genetic heterogenity and 
can be classiﬁed into seven major genotypes (HCV 1–7) including 67 conﬁrmed and 20 provisional 
subtypes, on the basis of phylogenetic analysis of genome sequences [3, 8]).  Hepatitis C virus (HCV) 
genome sequence is highly variable .  The nucleotide sequence differs by 31% to 33% among genotypes 
and by 20% to 25% among subtypes [4, 10, 11, 12].  HCV genotype distributions show different 
geographic patterns [8] and patients infected with HCV 1b subtype have a greater risk of progression to 
HCC than do those infected with other subtypes [13].  
One of molecular determination method performed to prove the presence of HCV RNA is Reverse 
Transcription Polymerase Chain Reaction (RT-PCR).  The HCV exhibits global genotypic diversity [8]. 
With RT-PCR technique on HCV nucleotides and sequencing on positive PCR products, HCV 
genotypes/subtypes can be identified [7, 14, 15, 16, 17].  
 There are several methods used to determine HCV genotypes, for example by using the direct 
sequencing of specific PCR amplified portion products of the virus (NS5, Core, E1 and 5’ UTR regions), 
often in combination with the phylogenetic analysis [[4].  Sequence analysis of NS5B for genotyping 
HCV provides precise genotype and subtype identification and an accurate epidemiological 
representation of circulating viral strains [12].  The highly conserved 5’ UTR is also an ideal region for 
genotyping of HCV [12].  Primers for determining HCV genotype based on NS5B HCV genome [15], 
NS5B and 5'UTR of HCV have also been proven success in subsequent studies [7, 16, 17].  
This study was performed the detection of  HCV infection and its genotype in patients at 
Hepatology Outpatient Clinic, Dr. Soetomo General Hospital, Surabaya. 
 
 2. Experimental Methods 
The study protocol was reviewed and approved by the Ethics Committees of Dr Soetomo General 
Hospital, Surabaya, Indonesia and informed consent was obtained from all the patients.   
Sera were collected from 70 patients at Hepatology Outpatient Clinic, Dr Soetomo General 
Hospital, Surabaya, Indonesia.  All sera were stored at 80°C until they were used.  All of the sera were 
tested for anti-HCV antibodies by enzyme immunoassay (EIA) technique for the quantitative detection 
of IgG antibodies against HCV in serum, using a kit from the Foresight HCV EIA Antibody Test Kit 
REF 1231-1031, according to the manufacturer’s instruction. The cut-off value which was used as a  
level limit of positive and negative result was determined every time the test was done, based on the 
calculation attached to the kit instructions.  
Blood retrieval at Hepatology Outpatient Clinic, Dr Soetomo General Hospital, Surabaya, 
Indonesia.  Sera separation and laboratory work were carried out at the Hepatitis Laboratory, Institute 
of Tropical Disease (ITD), Airlangga University, except anti-HCV antibodies were done in private 
laboratory.. 
 
Reverse transcription and PCR 
Sera with positive anti-HCV antibodies were continued for HCV RNA detection.  Hepatitis C 
virus RNA was extracted from 120 µl positive Anti-HCV sera, using a kit for extraction of viral RNA 
from Qiagen, according to the instruction in the kit, then it was reverse transcribed into cDNA and 
amplified using SuperScript One‑Step RT-PCR (Invitrogen, Tokyo, Japan) and one set of NS5B primer 
for this first round PCR that was used by Mori [18] previously.  The initial reaction was performed at 
45˚C for 30 min for cDNA synthesis and at 94˚C for 2 min for hot start,  followed by the first-round 
PCR over 35 cycles, with each cycle consisting of the temperature at 94°C 1 min, 45°C 1 min, and at 
72°C 2 min.  At each time of HCV RNA extraction, cDNA synthesis from HCV RNA and PCR for HCV, 
negative control  (destillated water) and positive control (samples that was known to be positive for 
HCV RNA), were also run and processed together with the sample.   In the first round PCR amplification 
reaction of NS5b region, agarose electrophoresis was not performed.  After first round PCR was 
performed, it was followed by the second-round PCR  under the same conditions PCR cycle described 
above.  For the second round PCR, we amplify NS5B HCV region sequences using Fermentas PCR Kit 
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reagents and various primers from the NS5B region [15], step by step.  For the second round PCR, firtst 
we used HC23, HC24, HC26 and HC28 primers.  At the end of PCR cycle, extension time was extended 
for 10 minutes at 72o C.  If it still gave negative result in electrophoresis after second round PCR, 
continued with the second round PCR step by step by using HC23, HC32 and HC34 primers, HC15 and 
HC16 primer respectively.  The sequences and positions of the NS5B primers used in this study are 
shown in Table 1.  
 
Table 1. PCR primers used for NS5b HCV amplification 
 
 
 The second round PCR products were electrophoresed in a 2% agarose gel containing 
ethidium bromide and visualized under UV illumination. 
 In the case of negative ampliﬁcation of the NS5B region, 5’ UTR sequences were targeted for 
ampliﬁcation by PCR.  In this analysis, HCV RNA was also reverse transcribed into cDNA and  
amplified using SuperScript One‑Step RT-PCR (Invitrogen, Tokyo, Japan) by using one set of primer 
5’UTR1 (sense; 5’-CCGGGAGAGC CATAGTGGTC-3’) and 5’UTR2 (antisense; 5’-
AGTACCACAAGGCCTTTCGC-3’), and another set of  primer prepared for second round PCR that 
used previously [16], with the same PCR condition as above.  The primers for second round PCR were 
5’UTR3 (sense; 5’-TGGTCTGCGGAACCGGTGAG-3’) and 5’UTR4 (antisense; 5’-
ACCCAACACTACTC GGCTAG-3’).  After the first round PCR amplification reaction of 5’UTR 
region, agarose electrophoresis was performed and it was not followed by second round PCR when 
electrophoresis gave positive result.  The PCR products were electrophoresed in a 3% agarose gel 
containing ethidium bromide and were visualized under UV illumination. 
If the amplification using the primers of the NS5B and 5’UTR regions above were gave negative 
result, the extracted RNA was reverse transcribed and amplified using the different set of NS5B primers: 
F1, R1 and F2, R2 that was used in another previous publication [19], as an effort for getting more 
positive result of HCV cDNA amplification. The PCR products were also electrophoresed in a 2% 
agarose gel containing ethidium bromide and it were visualized under UV illumination. 
 
Sequencing and genotype/subtype analysis of HCV.  
The positive PCR products based on NS5B or 5'UTR containing nucleotide fragments that had 
been amplified from the target HCV genome were purified using Qiagen gel purification kit according 
to the kit instructions and checked by electrophoresis. Then the purified nucleotide sequences of the 
ampliﬁed fragments were ampliﬁed again with the one of previously PCR primer and sequenced by 
direct sequencing method using BigDye Terminator Cycle Sequencing kit and an ABI Prism 310 
sequencer (Applied Biosystems, Foster City, CA, USA). 
Each obtained sequence from the NS5B HCV region was compared previously reported subtypes 
using the BLASTN program from NCBI on the internet.  The nucleotide sequences of the 5'UTR HCV 
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region were determined and compared with the consensus sequence motifs for each of the major 
genotypes previously reported [20].  
 
3. Results and Discussion 
From 70 patients who came to the Hepatology Out Patients Clinic of Dr. Soetomo, Surabaya, 41 (58.6%) 
male and 29 (41.4%) female patients, 17/70 (24.29%) was proven infected with HCV, marked by a 
positive Anti-HCV (Table 2).   
Table 2 :  Anti-VHC level 
Anti-HCV Male Female Total 





(-0,015) – (-0,102 ) 
21/29 (72,41%) 
0,025   
(-0,011) – (-0,049) 
53/70 (75,71%) 
 





(2,775 - 2,939) 
8/29 (27,59%) 
2,881 
(2,814 - 2,928) 
17/70 (24,29%) 
 
Total 41/70 (58,57%) 29/70 (41,43%) 70/70 (100%) 
   
When of antibodies to HCV were detected in individual (positive anti-HCV), indicates that the 
person has had previously infected or has current active infection with HCV [21].  However, when it 
was only anti-HCV positive, it is not yet known whether the person is in viremia condition / still has 
HCV or not, and we still need to prove whether HCV RNA is in his blood.    
 By using RT-PCR technique, HCV RNA detection from positive Anti-HCV sera has been 
carried out based on a part of NS5B HCV gene region, which is if necessary continued with PCR based 
on 5’UTR HCV. The NS5B and 5’UTR primers are quite sensitive and have been used in previous HCV 
studies [7, 15, 16, 17].  The results of HCV RNA detection on samples with positive Anti-VHC in this 
study are shown in Table 3 below. 
 
Table 3. Primers and HCV PCR result in HCV RNA detection. 
 PCR Round and Pair of Primers used 
 
Primer Position 
in HCV region 
Positives HCV 
on PCR 
First Round  and  #166, #167R 





First Round  and 5’UTR1 and 5’UTR2 5’UTR 5 
First Round  and  F1 and  R1 





All primer gives negative results NS5B and 5’UTR 1 
TOTAL  17 
 
 Detection of HCV RNA was performed in 17 positive anti-HCV samples and it was found that 
94,12% (16/17) samples had positive HCV RNA.  In the one of  the sample with positive anti-HCV, 
HCV RNA remains negative although for this detection we had used another NS5B primer pairs F1, R1, 
F2 and R2 [19] outside the NS5B previous #166, #167R and HC-primers, that was not proposed before. 
It was reported that 5’UTR based assays are reasonably accurate with more than 95% concordance with 
genotypes that have been identified by nucleotide sequencing of the NS5B region or other coding 
regions of the HCV genome [11, 12]. This results is in line with our previously results study in Surabaya, 
which suggested that 95% of samples with positive anti-VHC still contained positive HCV RNA [7].  
The high variability of HCV genome in Surabaya was proven that for getting 94,1% RNA HCV positive 
in anti-HCV positive sera in this study, it was needed the different NS5B primers [19] out of primers 
using by Soetjipto [7] in the same city.   
 In this study, one sample with positive anti-HCV still remain negative for HCV RNA.  From a 
similar study, the detection of HIV in the blood that got anti-HIV positive data but HIV RNA was 
negative, it were suggested the possibility of nucleotide mutations in the primers annealing regions, 
reducing the melting temperature, or low levels of virus in the blood below the threshold of sensibility, 
can cause detection of HIV RNA is negative in the samples with positive anti-HIV [22]. This statement 
CoSCI - PBBMI




may also happen in HCV infection in this study, considering the HCV genome sequence is highly 
variable [12] and the other possibility is HCV RNA disappeared after seroconversion [21].  
 In 16 sera with RT-PCR positive for HCV, sequencing tests were carried out and 16 HCV 
sequencing results were obtained. One negative sample on RT-PCR was not sequenced.  Sequencing 
results of these 16 HCV samples were then performed HCV genotype/subtype analysis.  Nucleotide 
sequences from HCV NS5B region were analyzed using the BLASTN program from NCBI on the 
internet and the nucleotide sequences of the 5'UTR region were determined and compared with the 
consensus sequence motifs for each of the major genotypes previously reported [20]. Genotyping 
methods based on the 5’UTR of HCV were important tools for routine clinical purposes because they 
were sufficiently precise at the genotype level [12].  The principle for determining the HCV 
genotypes/subtypes in the above way was to compare the nucleotides of samples to various nucleotides 
from various HCV genotypes/subtypes published previously.  In Table 4 below will be shown the results 
of the HCV genotypes/subtypes analysis. 
 





HCV genotype HCV Subtype 
1 2 1b 1c 2a 3a 3k 













     
F2 4   2/16 
(12,5%) 



















The HCV genotypes/subtypes were vary in various geographic areas [4, 23].  In sequence analysis 
of positive PCR results of HCV, if the positive results can be obtained from the NS5b region (in this 
study using sequencing primers HC23 and F2 ), it will obtain HCV subtype from the sequence analysis 
results. The use of primers F1, R1, F2 and R2 [19] is intended to get as many as possible HCV RNA 
from anti-HCV positives samples, considering that HCV genome sequence is highly variable [12].  If 
the positive results are obtained from the HCV 5'UTR region (in this study using 5’UTR1 sequencing 
primer), it will be obtain HCV genotype from the sequence analysis results.  5’UTR region of HCV is a 
conserved HCV region, so that nucleotide variations from various HCV genotypes are relatively low. 
Of the 16 HCV sequences in this study for HCV genotype/subtype analysis, 12,5% (2/16) is HCV 
genotype 1, 37.5% (6/16) is HCV subtype 1b, 6,25% (1/16 ) is HCV subtype 1c, 18,75% (3/16) is HCV 
genotype 2, 6,25% (1/16) is HCV subtype 2a, 12,5% (2/16) is HCV subtype 3a and 6,25% (1/16) is 
HCV subtype 3k.  In this study, HCV genotype 1 and HCV subtype 1b were still dominant in patients 
with liver disease in Surabaya, Indonesia, still as stated in the results of our previous study [7], but HCV 
subtype 3k was found in this study and HCV subtype 3g was found in our previous study.   The result 
study in Jakarta, Indonesia, the bigger city than Surabaya, based on HCV NS5B and 5’UTR region in 
liver disease patient  also found HCV subtype 1b (36,5%) was the most prevalent, followed by subtypes 
3k (15,4%), 2a (14,4%), 1a (12,5%),1c (12,5%), and 2e (4,8%) and subtypes 2f, 3a, 3b, and 4a were also 
found in some of the samples [24].  Utama [24] found more  varying HCV subtypes in Jakarta  than we 
found in Surabaya.  It was mentioned in the previous report, genotypes 1, 2 and 3 have a worldwide 
distribution [1, 6, 8], genotype 1 and 6 account over the 60% of all the genotypes identified (35.2% and 
30.8%, respectively) in Southeast Asia, followed by genotype 3 (19.9%) and 2 (11.1%) [4].  Beside 
HCV genotype and subtype are important indicators for antiviral therapeutic responses [25], HCV 
mutation in genotype 1b was related to the occurrence of HCC [13].  Subtype 1b of HCV has more 
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efficient viral replication ability, poor prognosis, possesses major proportion of severe liver disease 
(LD), and related Liver Cirrhosis and HCC than non-1b subtypes [5, 13].    
Considering 85% of HCV infections become chronic with a high risk of hepatocellular carcinoma 
[2] and HCV subtype 1b is dominant HCV subtype in this study, more attention for consideration and 
prevention in subsequent management of  HCV infection is required. This results of  HCV 
genotype/subtypes study also give additional information  to HCV genotype/subtypes diversity data in 
Indonesia and can be used as consideration for HCV therapy. 
 
4. Conclusion  
In patients who went to the Hepatology Outpatient Clinic, Dr. Soetomo General Hospital Surabaya, we 
found positive Anti-HCV was 24.29% (17/70).  In 94.1% (16/17) of patients with positive anti-HCV, 
HCV RNA was still detected. Genotype/subtype HCV analysis were found 2/16 (12.5%), 3/16 (18.75%) 
and 6/16 (37.5%), 1/16 (6.25%), 1/16 (6 , 25%), 2/16 (12.5%), 1/16 (6.25%) HCV genotypes 1, 2, and 
HCV subtypes 1b, 1c, 2a, 3a, 3k respectively, and HCV genotype 1 and subtype 1b were still dominant 
HCV subtype in Surabaya.  From the results of this study can be suggested further research in the 
molecular field to better understand the viral genotype distribution that affects the course of infection, 




[1] Lavanchy D. 2011.  Review.  Evolving epidemiology of hepatitis C virus. European Society of 
Clinical Microbiology and Infectious Diseases.  Clin Microbiol Infect. CMI, 17, 107–115. 
[2] Vyas, G. N. and Yen TSB. 1999. Hepatitis B Virus.  In: Specter, S. Viral Hepatitis. Diagnosis, 
Therapy and  Prevention.  Humana Press, Totowa, New Jersey. p: 35 -63. 
[3] Akbar H, Idrees M, Manzoor S, Rehman I, Butt S, Yousaf MZ, Rafique S, Awan Z,  Khubaib B, 
Akram M and Aftab M.  2009.  Hepatitis C virus infection: A review of the current and future 
aspects and concerns in Pakistan.  Journal of General and Molecular Virology Vol.1 (2), pp. 012-
018.  
[4] Petruzziello A, Marigliano S, Loquercio G, Cozzolino A and Cacciapuoti C.  2006.    Global 
epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of 
hepatitis C virus genotypes.   World J Gastroenterol, September 14; 22(34): 7824-7840. ISSN 
1007-9327 (print)  ISSN 2219-2840 (online). Baishideng Publishing Group Inc.  
[5] Zhang Y, Li-Min Chen LM and He M. 2017. Hepatitis C Virus in mainland China with an 
emphasis on genotype and subtype distribution.   Open Access: Virology Journal (2017) 14: 41 
DOI 10.1186/s12985-017-0710-z. 
[6] Lopes I, Teles CLRSA, Espírito-Santo MP, Lampe E, Rodrigues FP, Motta-Castro ARC, Marinho 
TA, Reis NR, Silva AMC, Martins RMB. 2009. Prevalence risk factors and genotypes of hepatitis 
C virus infection among drug users Central-Western Brazil.   Rev Saúde Pública; 43 (Supl. 1) p. 
1-7. 
[7] Soetjipto, Handajani R, Lusida MI, Darmadi S, Adi P, Soemarto R, Ishido S, Katayama Y, and 
Hotta H. 1996. Differential prevalence of hepatitis C virus subtypes in healthy blood donors, 
patients on maintenance hemodialysis, and patients with hepatocellular carcinoma in Surabaya, 
Indonesia.  J. Clin. Microbiol. 34: 2875-2880. 
[8] Chen Y, Yu C, Yin X, Guo X, Wu S and Hou J.  2017.  Hepatitis C virus genotypes and subtypes 
circulating in Mainland China.  Emerging Microbes & Infections 6, e95; doi:10.1038/emi.2017.77 
[9] Houghton M, Han J, Kuo G, Choo QL, Weiner AJ. 1993.  Structure and Molecular Virology of 
Hepatitis C virus.  In Zuckerman AJ, Thomas HC (eds). Viral Hepatitis, 1st Edition.  Scientific 
Basis and Clinical Management. London; Churchill Livingstone: 229-241. 
[10] Anderson JC, Simonetti J, Fisher DG, Williams J, Yamamura Y, Rodriguez N, Sullivan DG, 
Gretch DR, McMahon B, Williams KJ. 2003.  Comparison of different HCV viral load and 
genotyping assays.  J Clin Virol; 28: 27-37 [PMID: 12927748 DOI: 10.1016/ S1386-
6532(02)00235-4]  
[11] Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, 
Kuiken C, Maertens G, et al.  2005.  Consensus proposals for a unified system of nomenclature 
of hepatitis C virus genotypes.  Hepatology 2005, 42(4):962-973. 
CoSCI - PBBMI




[12] Nakatani SM, Santos CA, Riediger IN, Marco A Krieger MA, Duarte CAB, Debur MdoCB, 
Carrilho FJ and Ono SK. 2011. Comparative performance evaluation of hepatitis C virus 
genotyping based on the 5’untranslated region versus partial sequencing of the NS5B region of 
Brazilian patients with chronic hepatitis C. Virology Journal, 8:459 
http://www.virologyj.com/content/8/1/459  
[13] Nishise Y, Saito T, Sugahara K, Ito J-i, Saito K, Togashi H, Fujii MN. Hotta H and Kawata S. 
2007. Brief Report. Risk of Hepatocellular Carcinoma and Secondary Structur of Hepatitis C 
Virus.  JID: 196: 100-1009.  
[14] Hotta, H., R. Handajani, M. I. Lusida, W. Soemarto, H. Doi, H. Miyajima, and M. Homma. 1994. 
Subtype analysis of hepatitis C virus in Indonesia on the basis of NS5b region sequences.  J. Clin. 
Microbiol. 32:3049–3051.  
[15] Apichartpiyakul C, Chittivudikarn C, Miyajima H, Homma M, and Hotta H. 1994. Analysis of 
hepatitis C virus isolates among healthy blood donors and drug addicts in Chiang Mai, Thailand.  
J. Clin. Microbiol. 32: 2276–2279. 
[16] Doi H, Apichartpiyakul C, Ohba KI, Mizokami M and Hotta H. 1996.  Hepatitis C virus (HCV) 
subtype prevalence in Chiang Mai, Thailand, and identification of novel subtypes of HCV major 
type 6.  J Clin Microbiol 34: 569‑574. 
[17] Juniastuti, Utsumi T,  Nasronudin, Alimsardjono L, Amin M, Adianti M, Yano Y,  Soetjipto, 
Hayashi Y,  Hotta H  and Lusida MI. 2014.  High rate of seronegative HCV infection  in 
HIV‑positive patients.  Biomedical report, 2:  79-84. 
[18] Mori S, Kato N, Yagyu T, Tanaka Y, Ikeda B, Petchlai P, Chiewsilp T, Kurimura T and 
Shimotohno K. 1992.  A new type of Hepatitis C Virus in patients in Thailand.  Biochem. Biophys. 
Res. Commun. 183:334-342. 
[19] Anggorowati  N, Yano Y, Heriyantto DS, Rinonce HT, Utsumi T, Mulya DP, Subronto YW, and 
Hayashi Y. 2012.  Clinical and Virological Characteristic of Hepatitis B or C Virus co-Infection 
with HIV in Indonesian Patients.  J Med Virol. 84 (6): 857-865. 
[20] Kleter GE, van Doorn LJ, Brouwer JT, Schalm SW, Heijtink RA and Quint WG.  1994. Sequence 
analysis of the 5' untranslated region in isolates of at least four genotypes of hepatitis C virus in 
The Netherlands.  J Clin Microbiol 32: 306‑310. 
[21] Hilfenhaus J, Krupka U, Nowak T, et al. 1992. Follow up of Hepatitis C virus infection in 
Chimpanzees: Determination of viraemia and specific humoral immune response.  J.Gen.Virol.; 
73 : 1015-1019. 
[22] Bounaguro L, Petrizzo A, Tagliamonte M, Vitone F, Re MC, Pilotti E, Casoli C, Sbreglia F, 
Perella O, Tornesello ML, and Bounaguro FM. 2008.  Molecular and Phylogenetic analysis of 
HCV-1 Variant circulating in Italy.  Infectious Agents and Cancer; 3:13, pp.1-12. 
[23] Idrees M, and Riazuddin S.  2008.  Research article. Frequency distribution of hepatitis C virus 
genotypes in different geographical regions of Pakistan and their possible routes of transmission. 
BMC Infectious Diseases, 8:69 doi:10.1186/1471-2334-8-69 
[24] Utama A, Budiarto BR, Monasari D, Octavia TI, Chandra IS, Gani RA. Hasan I, Sanityoso A, 
Miskad UA, Yusuf I, Lesmana LA, Sulaiman A, Tai S. 2008.  Hepatitis C Virus Genotype in 
Blood Donors and Associated Liver Disease in Indonesia. Intervirology 2008;51:410–416.  
[25] Cuypers L, Ceccherini-Silberstein F, Van Laethem K et al. 2016.  Impact of HCV genotype on 
treatment regimens and drug resistance: a snapshot in time. Rev Med Virol; 26: 408–434.  
 
Acknowledgments  
We are grateful to all participants in this study. This study was supported by a competitive grant for 
research (PTUPT) from Ministry of Higher Education of Indonesia.   
 
